CZChunying Zhang

Chunying Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chunying Zhang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development and Validation of a Machine Learning Diagnostic Model Using Routine Clinical Data to Differentiate Malignant from Benign Pericardial Effusion

    by Shuang Sun, Ziqi Song, Mei Zhao, Lin Pei, Jing Song, Chunying Zhang, Cheng Chi, Jian Liu, Junxian Song

    Objectives: This study aimed to develop and validate a machine learning model based on routine clinical data to provide real-time, accurate decision support for distinguishing malignant pericardial effusion (MPE) from benign pericardial effusion (BPE). Methods: In total, 296 patients were retrospectively enrolled, comprising 168 with BPE and 128 with MPE. The dataset was randomly divided into training and test sets in a 7:3 ratio. Six machine learning algorithms were trained to construct predictive models, with their predictive accuracy assessed using the Area Under the Curve (AUC) and Decision Curve Analysis (DCA). Furthermore, SHapley Additive exPlanations (SHAP) analysis was utilized to interpret model outputs and identify key predictive variables. Results: All six machine learning models achieved favorable diagnostic performance. Among them, the LightGBM (LGB) model demonstrated the highest predictive accuracy; the LGB test set under the receiver operating characteristic curve (AUC) was 0.930 (95% CI 0.871–0.979), with a sensitivity of 86.8%, a specificity of 94.0%, and an accuracy of 90.9%. XGBoost (XGB) had a lower score than LGB (0.111 versus 0.142). LGB calibration intercept and slope were 0.246 and 3.328. The combined serum D-dimer/carbohydrate antigen 125 (CA125) model had AUC 0.876; its difference from LGB was uncertain (ΔAUC 0.054, 95% CI −0.011 to 0.125; Holm-adjusted p = 0.382). Mean LGB out-of-fold AUC was 0.888 (SD 0.008). Fluid lactate dehydrogenase had the highest SHAP importance. Conclusions: This study developed and validated an interpretable machine learning model incorporating five readily available clinical indicators that enables accurate and rapid differentiation between MPE and BPE, enhancing diagnostic decision-making for pericardial effusion.

  • Open Access

    VEGFC/VEGFR3 Signaling‐Dependent Lymphatic Remodeling Modulates Cardiac Response to Pressure Overload

    by Lina Su, Yuxia Cui, Manyan Wu, Shiran Yu, Chunying Zhang, Ziqi Song, Shuolei Li, Hang Lin, Zheng Lian, Chongyou Lee, et al.

    Background: Cardiac lymphangiogenesis has been proposed as a potential therapeutic target to prevent the development of heart failure. However, the efficiency of systemically delivered VEGFC ( vascular endothelial growth factor C) protein in inducing cardiac lymphangiogenesis has shown inconsistency across different studies. Moreover, the mechanisms underlying lymphatic remodeling during heart failure remain poorly understood. Methods: To determine the role of lymphatic remodeling in heart failure, we used adeno‐associated virus–mediated gene therapy to either inhibit VEGFR3 ( vascular endothelial growth factor receptor 3) expression or enhance VEGFC expression in mice subjected to transverse aortic constriction. In vitro studies were further conducted to investigate the role of Yes‐associated protein in VEGFC/VEGFR3 signaling in lymphatic endothelial cells. Results: Our study shows that transverse aortic constriction induces dynamic lymphatic remodeling, characterized by an early adaptive cardiac lymphangiogenic response and enhanced peripheral lymphatic transport function. Adeno‐associated virus‐sh‐VEGFR3 treatment inhibited this early adaptive lymphangiogenesis, exacerbating cardiac inflammation and adverse remodeling. Conversely, adeno‐associated virus–VEGFC therapy appeared to be cardioprotective by promoting adaptive lymphangiogenesis and facilitating the resolution of cardiac inflammation. Moreover, adeno‐associated virus–VEGFC treatment improved peripheral lymphatic drainage function, potentially alleviating peripheral congestion in heart failure. Further in vivo and in vitro analyses revealed that Yes‐associated protein dephosphorylation is essential for VEGFC/VEGFR3 signaling‐dependent lymphangiogenesis and for upregulation of lymphatic chemokines and scavenger receptors. Conclusions: These findings highlight that targeting cardiac lymphangiogenesis via VEGFC/VEGFR3 signaling through genetic approaches represents a promising therapeutic strategy for heart failure. Moreover, VEGFC administration may offer a novel, noninvasive decongestive approach by modulating the lymphatic system in heart failure management.